Why the study?
Recent studies suggested β1-blockers may reduce bleeding risk, but their association with bleeding outcomes in patients receiving potent DAPT after ACS or PCI required evaluation.
Does β1-blocker treatment reduce bleeding risk in patients with ACS or undergoing PCI treated with ticagrelor and aspirin?
Does β1-blocker treatment reduce bleeding risk in patients with ACS or undergoing PCI treated with ticagrelor and aspirin?
In patients receiving potent dual antiplatelet therapy with ticagrelor and aspirin after ACS or PCI, concomitant β1-blocker therapy is associated with a significantly reduced risk of clinically relevant bleeding.
Answers are grounded in this paper and cite their sources.
β1-blockers may lower bleeding on ticagrelor DAPT; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: β1-blockers could improve clinical outcomes in patients with coronary artery disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover, recent studies have suggested that β1-blockers may also have the potential to reduce bleeding risk. OBJECTIVES: This study aimed to evaluate the association between β1-blockers and bleeding risk in the patients prescribed with potent dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI). METHODS: Patients with ACS or undergoing PCI treated by DAPT of ticagrelor and aspirin were consecutively recruited. Follow-up for all eligible patients was conducted for 1 year. Major bleeding outcomes were defined as events that were type ≥2 based on the Bleeding Academic Research Consortium (BARC) criteria. RESULTS: A total of 1,113 eligible ticagrelor-treated patients were recruited. During the 1-year follow-up interval, 142 (12.6%) patients experienced BARC ≥2 bleedings including 23 patients (2.1%) suffering BARC ≥3 bleedings, with the most common site of bleeding located in the gastrointestinal tract. β1-blockers treatment was associated with a lower risk of BARC ≥2 bleedings (11.2% vs. 23.3%, adjusted HR: 0.42, 95% CI: 0.28-0.62, P < 0.01). Moreover, metoprolol (11.1% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.37-0.83, P < 0.01) and bisoprolol (11.3% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.33-0.96, P = 0.04) had similar effects on the reduction of bleeding risk. CONCLUSION: β1-blockers might be beneficial for the reduction of bleeding risk in potent dual antiplatelet therapy patients with ACS or undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: